Armed with a PhI cancer drug from Bayer, an Acerta founder breaks cover and writes himself a $60M blank check deal
Ahmed Hamdy has been busy.
This morning Hamdy — one of the key co-founders at Acerta — jumped out of stealth mode with a new biotech that has a small but significant pipeline, including one cancer drug in Phase I development. And he’s vaulted fully into the open, leaping onto Wall Street through a SPAC that leaves the company with $60 million in its coffers to do something with its drugs.
Now they’ll start trading as $VINC.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.